Patents Examined by Kathrien A Cruz
  • Patent number: 10435367
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 8, 2019
    Assignees: City of Hope, The National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, Richard Jove, Leandros Skaltsounis
  • Patent number: 10420812
    Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 24, 2019
    Assignee: Infirst Healthcare Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 10405546
    Abstract: The present invention provides an aqueous suspoemulsion comprising (a) an oil phase comprising (i) at least one triazole active compound as emulsified component, solid at room temperature, (ii) at least one alkyl carboxylic acid amide as a solvent and a crystal growth inhibitor, and (iii) a polymeric stabilizer, and (b) a continuous water phase comprising (i) at least one strobilurin active compound as suspended solid component, solid at room temperature, (ii) at least one dispersant selected from the group consisting of methacrylic acid-methyl methacrylate-polyethyleneglycol graft copolymer, tristyrylphenolethoxylates and/or propylene oxide/ethylene oxide block copolymer with 10% to 50% EO, preferably with 20% to 50% EO and most preferably with 30% to 40% EO, (iii) water, and (iiii) additives, if appropriate. a process for preparing the suspoemulsion and its use for applying the active compounds comprised therein to plants and/or their habitat are also provided.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: September 10, 2019
    Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED
    Inventors: Antonio Carlos Damaceno, Jose Gilberto Hermann
  • Patent number: 10391093
    Abstract: The invention provides compounds of formulae I, II, III, and IV: and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: August 27, 2019
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Carl E. Wagner, Peter W. Jurutka, Pamela A. Marshall
  • Patent number: 10383857
    Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 20, 2019
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Gregory Hebrank, Thomas Petzinger, Jr., Steven Dworetzky, Wildon Farwell
  • Patent number: 10336743
    Abstract: Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1?1, CK1?2, CK1?3, CK2, Pim 1, Pim2, Pim3, the TGF? pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1?1, CK1?2, CK1?3, CK2, Pim 1, Pim2, Pim3, the TGF? pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 2, 2019
    Assignee: Jasco Pharmaceuticals, LLC
    Inventors: Carmen M. Baldino, Justin L. Caserta, Chee-Seng Lee, Stephane A. Dumas, Yvonne L. Flanders
  • Patent number: 10336735
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: July 2, 2019
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Luke Lairson, Arnab K. Chatterjee, Michael Bollong, Baiyuan Yang, Peter G. Schultz
  • Patent number: 10322098
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 18, 2019
    Assignee: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • Patent number: 10322138
    Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 18, 2019
    Assignee: PHERIN PHARMACEUTICALS, INC.
    Inventor: Louis Monti
  • Patent number: 10307376
    Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: June 4, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Anthony A. McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
  • Patent number: 10292954
    Abstract: The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RAR? agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: May 21, 2019
    Assignee: Thomas Jefferson University
    Inventors: Masahiro Iwamoto, Maurizio Pacifici
  • Patent number: 10285980
    Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 14, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventors: Samit Hirawat, Langdon Miller
  • Patent number: 10272082
    Abstract: Provided is a method for treating ALS in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., Cmax and/or AUC24h) in a subject, methods of reducing the variability of riluzole exposure (e.g., Cmax and/or AUC24h) between two or more subjects, methods of decreasing the total daily dose of riluzole in a subject, methods of increasing the half-life of riluzole in a subject, methods for decreasing the frequency of riluzole dosing in the subject, and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Jesse Cedarbaum, John Mao, Fady Malik, Andrew A. Wolff
  • Patent number: 10267796
    Abstract: Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR?1 receptors, and determining based on the binding interaction of the test agent with the ADR?1 receptors whether the test agent is an effective ADR?1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR?1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: April 23, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Leo Timothy Laughlin, II, Tomohiro Hakozaki, Wenzhu Zhao, Jiazhen Wang, John Crist Bierman
  • Patent number: 10258594
    Abstract: Disclosed is a semiochemical composition including methyl palmitate, methyl linoleate, methyl oleate methyl stearate, methyl laurate, methyl myristate, salts thereof, derivatives thereof, isomers thereof and/or structural analogues thereof that have an appeasing effect in cats and/or also effects social facilitation in cats, and an acceptable vehicle. Solutions such as spot-on formulations of long duration are also encompassed. Methods to effect appeasing in a cat and/or social facilitation in cats are also disclosed.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Patent number: 10258593
    Abstract: A semiochemical composition including methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is described. Methods to reduce social conflicts in multi-cat households or in catteries or kennels boarding cats are also disclosed, as well as methods for inducing social facilitation in cats.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Patent number: 10238661
    Abstract: Disclosed are methods for treating various bacterial infections with (2R,4S,4aS)-11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2?H,6H-spiro[1,4-oxazino[4,3-a][1,2]oxazolo[4,5-g]quinoline-5,5?-pyrimidine]-2?,4?,6?(1?H,3?H)-trione, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: March 26, 2019
    Assignee: Entasis Therapeutics Limited
    Inventor: Michael Huband
  • Patent number: 10238669
    Abstract: This document provides methods and materials involved in treating cardiovascular conditions such as calcific aortic valve stenosis. For example, methods and materials for using sGC agonists or a combination of sGC agonists and PDE5A inhibitors to reduce calcification of heart valves and/or vessels or to slow progression of aortic sclerosis to calcific aortic valve stenosis are provided.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 26, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Jordan D. Miller, Bin Zhang
  • Patent number: 10226475
    Abstract: A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3?,7?-dihydroxycholest-5-en-26-oic (3?,7?-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: March 12, 2019
    Assignee: SWANSEA UNIVERSITY
    Inventors: Ernest Arenas, William Griffiths, Yuqin Wang, Spyridon Theofilopoulos
  • Patent number: 10220028
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 5, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Harold W. Holloway, Qian-Sheng Yu, Edward J. Goetzl